The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype
Abstract
Purpose: To evaluate the relevance of breast cancer subtypes for magnetic resonance imaging (MRI) markers for monitoring of therapy response during neoadjuvant chemotherapy (NAC). Patients and Methods: MRI examinations were performed in 188 women before and during NAC. MRI interpretation included lesion morphology at baseline, changes in morphology, size, and contrast uptake kinetics (initial and late enhancement). By using immunohistochemistry, tumors were divided into three subtypes: triple negative, human epidermal growth factor receptor 2 (HER2) positive, and estrogen receptor (ER) positive/HER2 negative. Tumor response was assessed dichotomously (ie, presence or absence of residual tumor in the surgical specimen). Complementary, a continuous scale assessment was used (the breast response index [BRI], representing the relative change in tumor stage). Multivariate regression analysis and receiver operating characteristic analysis were employed to establish significant associations. Results: Residual tumor at pathology was present in 31 (66%) of 47 triple-negative tumors, 23 (61%) of 38 HER2-positive tumors, and 96 (93%) of 103 ER-positive/HER2-negative tumors. Multivariate analysis of residual disease showed significant associations between breast cancer subtype and MRI (area under the curve [AUC], 0.84; P < .001). BRI also showed significant correlation among breast cancer subtype, MRI, and age (Pearson's r = 0.465; P < .001). In subset analysis, this was only significant for triple-negative tumors (P < .001) and HER2-positive tumors (P < .05). Residual tumor after NAC in the triple-negative and HER2-positive group is significantly associated with the change in largest diameter of late enhancement during NAC (AUC, 0.76; P < .001). No associations were found for ER-positive/HER2-negative tumors. Conclusion: MRI during NAC to monitor response is effective in triple-negative or HER2-positive disease but is inaccurate in ER-positive/HER2-negative breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Fisher, E. R., Wickerham, D. L., Wolmark, N., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2483 · Cited by 1,801
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
The molecular portraits of breast tumors are conserved across microarray platforms
Hu, Z., Fan, C., Oh, D. S., Marron, J., He, X., Qaqish, B. F., Livasy, C., Carey, L. A., Reynolds, E., Dressler, L., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-96 · Cited by 1,491
Wolmark, N., Wang, J., Mamounas, E., Bryant, J., & Fisher, B. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003469 · Cited by 1,299
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
van der Hage, J. A., van de Velde, C. J. H., Julien, J.-P., Tubiana-Hulin, M., Vandervelden, C., Duchateau, L., & Cooperating Investigators (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4224 · Cited by 1,107
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., & Sotiriou, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4756 · Cited by 828
Fisher, E. R., Wang, J., Bryant, J., Fisher, B., Mamounas, E., & Wolmark, N. (2002) · Cancer · doi:10.1002/cncr.10741 · Cited by 413
Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings
Uematsu, T., Kasami, M., & Yuen, S. (2009) · Radiology · doi:10.1148/radiol.2503081054 · Cited by 344
von Minckwitz, G., Kummel, S., Vogel, P., Hanusch, C., Eidtmann, H., Hilfrich, J., Gerber, B., Huober, J., Costa, S. D., Jackisch, C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn085 · Cited by 296
Chollet, P., Amat, S., Cure, H., de Latour, M., Le Bouedec, G., Mouret-Reynier, M.-A., Ferriere, J.-P., Achard, J.-L., Dauplat, J., & Penault-Llorca, F. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600210 · Cited by 259
Padhani, A. R., Hayes, C., Assersohn, L., Powles, T., Makris, A., Suckling, J., Leach, M. O., & Husband, J. E. (2006) · Radiology · doi:10.1148/radiol.2392021099 · Cited by 236
Pickles, M. D., Lowry, M., Manton, D. J., Gibbs, P., & Turnbull, L. W. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-5819-2 · Cited by 213
Changes in Gene Expression Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer
Hannemann, J., Oosterkamp, H. M., Bosch, C. A. J., Velds, A., Wessels, L. F. A., Loo, C., Rutgers, E. J., Rodenhuis, S., & van de Vijver, M. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.077 · Cited by 205
Self-citationManton, D. J., Chaturvedi, A., Hubbard, A., Lind, M., Lowry, M., Maraveyas, A., Pickles, M. D., Tozer, D. J., & Turnbull, L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602948 · Cited by 197
Chen, J. H., Feig, B., Agrawal, G., Yu, H., Carpenter, P. M., Mehta, R. S., Nalcioglu, O., & Su, M. Y. (2008) · Cancer · doi:10.1002/cncr.23130 · Cited by 182
de Ronde, J. J., Hannemann, J., Halfwerk, H., Mulder, L., Straver, M. E., Vrancken Peeters, M.-J. T. F. D., Wesseling, J., van de Vijver, M., Wessels, L. F. A., & Rodenhuis, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0499-6 · Cited by 167
Self-citationManton, D. J., Chaturvedi, A., Hubbard, A., Lind, M., Lowry, M., Maraveyas, A., Pickles, M. D., Tozer, D. J., & Turnbull, L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603165 · Cited by 162
Wang, Y., Ikeda, D. M., Narasimhan, B., Longacre, T. A., Bleicher, R. J., Pal, S., Jackman, R. J., & Jeffrey, S. S. (2008) · Radiology · doi:10.1148/radiol.2462070169 · Cited by 157
Endocrine therapy – current benefits and limitations
Nicholson, R. I., & Johnston, S. R. D. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9036-4 · Cited by 145
The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
Straver, M. E., Rutgers, E. J. T., Rodenhuis, S., Linn, S., Loo, C. E., Wesseling, J., Russell, N. S., Oldenburg, H. S. A., Antonini, N. F., & Peeters, M.-J. T. F. D. V. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1008-1 · Cited by 133
Self-citationTrastuzumab and breast cancer: developments and current status
Tokunaga, E., Oki, E., Nishida, K., Koga, T., Egashira, A., Morita, M., Kakeji, Y., & Maehara, Y. (2006) · International Journal of Clinical Oncology · doi:10.1007/s10147-006-0575-4 · Cited by 103
Triple-negative breast cancer: MRI features in 29 patients
Chen, J.-H., Agrawal, G., Feig, B., Baek, H., Carpenter, P. M., Nalcioglu, O., Su, M., & Mehta, R. S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm504 · Cited by 75
Moon, H., Han, W., Lee, J. W., Ko, E. S., Kim, E., Yu, J. H., Kang, S. Y., Moon, W. K., Cho, N., Park, I.-A., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn683 · Cited by 59
Gilhuijs, K. G. A., Deurloo, E. E., Muller, S. H., Peterse, J. L., & Kool, L. J. S. (2002) · Radiology · doi:10.1148/radiol.2253011582 · Cited by 54
Self-citationChuthapisith (1994) · Oncology Reports · doi:10.3892/or_00000062 · Cited by 21
Heywang-Köbrunner, S. H. (2009) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(09)79247-1 · Cited by 11
Cited by
Mann, R. M., Cho, N., & Moy, L. (2019) · Radiology · doi:10.1148/radiol.2019182947 · Cited by 917
Houssami, N., Macaskill, P., von Minckwitz, G., Marinovich, M. L., & Mamounas, E. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.023 · Cited by 548
Donker, M., Straver, M. E., Wesseling, J., Loo, C. E., Schot, M., Drukker, C. A., van Tinteren, H., Sonke, G. S., Rutgers, E. J. T., & Vrancken Peeters, M.-J. T. F. D. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000558 · Cited by 429
Self-citationPartridge, S. C., Zhang, Z., Newitt, D. C., Gibbs, J. E., Chenevert, T. L., Rosen, M. A., Bolan, P. J., Marques, H. S., Romanoff, J., Cimino, L., et al. (2018) · Radiology · doi:10.1148/radiol.2018180273 · Cited by 288
Performance of FDG PET/CT in the Clinical Management of Breast Cancer
Groheux, D., Espié, M., Giacchetti, S., & Hindié, E. (2013) · Radiology · doi:10.1148/radiol.12110853 · Cited by 271
Metadata
- Authors
- Loo, C. E., Straver, M. E., Rodenhuis, S., Muller, S. H., Wesseling, J., Vrancken Peeters, M.-J. T. F. D., & Gilhuijs, K. G. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-02-20
- Volume
- 29
- Issue
- 6
- Pages
- 660-666
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166457180
- Cited by
- 304
- References
- 29
- FWCI
- 19.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.